Barton H A, Clewell H J
K.S. Crump Group, Inc., ICF Consulting, Research Triangle Park, NC, USA.
Environ Health Perspect. 2000 May;108 Suppl 2(Suppl 2):323-34. doi: 10.1289/ehp.00108s2323.
Alternatives for developing chronic exposure limits for noncancer effects of trichloroethylene (TCE) were evaluated. These alternatives were organized within a framework for dose-response assessment--exposure:dosimetry (pharmacokinetics):mode of action (pharmacodynamics): response. This framework provides a consistent structure within which to make scientific judgments about available information, its interpretation, and use. These judgments occur in the selection of critical studies, internal dose metrics, pharmacokinetic models, approaches for interspecies extrapolation of pharmacodynamics, and uncertainty factors. Potentially limiting end points included developmental eye malformations, liver effects, immunotoxicity, and kidney toxicity from oral exposure and neurological, liver, and kidney effects by inhalation. Each end point was evaluated quantitatively using several methods. Default analyses used the traditional no-observed adverse effect level divided by uncertainty factors and the benchmark dose divided by uncertainty factors methods. Subsequently, mode-of-action and pharmacokinetic information were incorporated. Internal dose metrics were estimated using a physiologically based pharmacokinetic (PBPK) model for TCE and its major metabolites. This approach was notably useful with neurological and kidney toxicities. The human PBPK model provided estimates of human exposure doses for the internal dose metrics. Pharmacodynamic data or default assumptions were used for interspecies extrapolation. For liver and neurological effects, humans appear no more sensitive than rodents when internal dose metrics were considered. Therefore, the interspecies uncertainty factor was reduced, illustrating that uncertainty factors are a semiquantitative approach fitting into the organizational framework. Incorporation of pharmacokinetics and pharmacodynamics can result in values that differ significantly from those obtained with the default methods.
对制定三氯乙烯(TCE)非致癌效应的慢性暴露限值的替代方法进行了评估。这些替代方法被组织在一个剂量反应评估框架内——暴露:剂量测定(药代动力学):作用方式(药效动力学):反应。该框架提供了一个一致的结构,在其中对现有信息、其解释和使用做出科学判断。这些判断发生在关键研究的选择、内剂量指标、药代动力学模型、药效动力学种间外推方法以及不确定性因素的确定过程中。潜在的限制终点包括发育性眼部畸形、肝脏效应、免疫毒性以及经口暴露引起的肾脏毒性,还有吸入引起的神经、肝脏和肾脏效应。每个终点都使用几种方法进行了定量评估。默认分析使用传统的未观察到不良反应水平除以不确定性因素以及基准剂量除以不确定性因素的方法。随后,纳入了作用方式和药代动力学信息。使用基于生理学的三氯乙烯及其主要代谢物的药代动力学(PBPK)模型估计内剂量指标。这种方法在神经毒性和肾脏毒性方面特别有用。人类PBPK模型为内剂量指标提供了人体暴露剂量的估计值。药效动力学数据或默认假设用于种间外推。对于肝脏和神经效应,当考虑内剂量指标时,人类似乎并不比啮齿动物更敏感。因此,种间不确定性因素降低了,这说明不确定性因素是一种适合该组织框架的半定量方法。纳入药代动力学和药效动力学可能会导致与默认方法得出的值有显著差异的值。